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A convergent synthesis for erythropoietin (EPO) 1-28 N-glycopeptide hydrazides
was developed. In this approach, EPO 1-28 peptides were synthesized on the solid
phase and converted to C-terminal hydrazides after cleavage from the resin. After
selective deprotection of the Asp24 side chain, the desired glycosylamine was
coupled by pseudoproline-assisted Lansbury aspartylation. Although the initial yields
of the EPO 1-28 glycopeptides were satisfactory, they could be markedly improved
by increasing the purity of the peptide using a reversed-phase high-performance liq-
uid chromatography (RP-HPLC) purification of the protected peptide.
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1 | INTRODUCTION
Erythropoietin (EPO) is a cytokine needed for the homeostasis of
erythrocytes. Therapeutic EPO is expressed recombinantly in Chinese
hamster ovary (CHO) cells and used mainly to treat anemic patients
suffering from renal failure or cancer.1 Owing to its high therapeutic
relevance, human EPO is one of the best studied glycoproteins. The
biological activity of EPO is modified by the sugar part2; however, the
inherent microheterogeneity of glycoproteins at each glycosylation
site precludes the availability of pure glycoforms for detailed
structure–activity studies. The presence of three N-glycans is crucial
for the biological activity of recombinant EPO, because non-
glycosylated EPO expressed in Escherichia coli is suffering from low
stability and a short serum half-life.3–6 Thus, a number of solubility-
enhancing mutations need to be introduced when expressing non-
glycosylated EPO.7 Additionally, the presence of a single glycan can
significantly stabilize EPO against aggregation.8
Single pure glycoforms of glycoproteins are currently available
only by synthetic methodology.9 Despite its complexity (three N-
glycans and one O-glycan), a number of EPO glycoforms and variants
were successfully synthesized, providing the protein with natural or
surrogate linkages for the glycans.8,10–19 Synthetic approaches for
EPO based on native chemical ligation require the synthesis of several
glycopeptide building blocks with a length of up to 40 amino acids.
The convergent synthesis of N-glycopeptides following the
aspartylation method developed by Lansbury20 involves the coupling
of a glycosylamine to an aspartyl side chain of a protected peptide.
Activation of the aspartyl side chain carboxylate by coupling reagents
can lead to an extensive formation of aspartimide and other
byproducts. These side reactions can be significantly reduced by using
a pseudoproline-assisted Lansbury aspartylation either in solution21 or
on the solid phase.22 This methodology takes advantage of the Asn-X-
Ser/Thr sequon for N-glycosylation. It was found that within this
sequon, the incorporation of an n+2 Ser/Thr pseudoproline efficiently
reduces the formation of aspartimide both during the synthesis of the
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peptide and in the subsequent coupling to the glycan.22 Even though
pseudoprolines are widely used in peptide synthesis, a mechanistic
explanation of how pseudoprolines efficiently reduce the formation of
aspartimides remains to be established.
A frequently used ligation site for EPO is Cys29 whereby EPO
1-28 glycopeptide thioesters23 are coupled with synthetic or recombi-
nant24 EPO 29-166 fragments. We are attempting the synthesis of
small libraries of EPO with a defined N-glycosylation pattern. Towards
this endeavor, EPO 1-28 glycopeptides were found to be versatile
building blocks serving for the synthesis of EPO variants with one N-
glycan (N24, see Figure 1). Herein, we present a systematic investiga-
tion of the large-scale convergent synthesis of EPO 1-28 glycopeptide
hydrazides25 suitable for native chemical ligation.
We found that the efficient synthesis of EPO 1-28 glycopeptides
requires a high purity of both the glycosylamine and the selectively
deprotected peptide. A key feature of this approach was the estab-
lishment of conditions allowing the prepurification of the protected
EPO 1-28 hydrazide building blocks using nonaqueous reversed-
phase high-performance liquid chromatography (RP-HPLC).26
2 | RESULTS AND DISCUSSION
As shown before,22 EPO 1-28 glycopeptides can be synthesized on
the solid phase in a straightforward manner. The aspartate of the N-
glycosylation site 24 was protected with an allyl ester.22 After mild
cleavage from the resin, the 1-28 glycopeptides were converted to a
thioester.22,27 The glycopeptide thioester containing GlcNAc gave an
overall yield of 37%. In contrast, the yields of the corresponding glyco-
peptide thioester containing a biantennary N-glycan nonasaccharide
reached only 24% owing to retention of the glycopeptide on the solid
phase.22 This led to a redesigned strategy where the peptide carrying
a C-terminal hydrazide serving as a latent thioester is synthesized first,
and after Asp side chain deprotection, the desired glycan can be
coupled in solution.28 To avoid residual palladium species in the pep-
tide after Pd-catalyzed deallylation22,29 in solution Asp24 was protec-
ted with a phenylisopropyl ester.30 Cysteine7 was protected as a
mixed disulfide, reducing the risk of oxidation after global
deprotection of the peptide.
The EPO 1-28 peptide was assembled on Fmoc-Gly-trityl-
ChemMatrix resin (1)31 incorporating two pseudoproline dipeptides
(see Figure 2). After mild cleavage from the resin (2), the protected
peptidyl acid 3 was converted to the Boc-hydrazide 4 using DIC/Cl-
HOBt and tert-butyl carbazate in analogy to the in situ
thioesterification method developed by Flemer.27 Peptide 4 was puri-
fied by flash chromatography. A brief treatment of 4 with 1%
trifluoroacetic acid (TFA) in dichloromethane (DCM) cleaved the
phenylisopropyl ester of Asp24 selectively, and the aspartyl peptide
5 was precipitated with diethylether. Gratifyingly, the course of the
deprotection could be followed by RP-LC–MS of the protected pep-
tides 4 and 5, revealing some loss of the acetonides (M-40) of the two
pseudoprolines. The pseudoproline-assisted Lansbury aspartylation
F IGURE 1 Retrosynthesis of erythropoietin (EPO) glycoforms A with a single N-glycan at Asn24. The building blocks B and C can be joined
by a native chemical ligation at Cys29. The glycopeptide thioester B is accessible via a convergent glycopeptide synthesis from the glycosylamine
E and the hydrazide D with a free Asp side chain at the glycosylation site 24
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was carried out by activating peptide 5 (1.5 eq.) with HATU/HOAt
and subsequent addition of freshly prepared biantennary
glycosylamine 7 (1.0 eq.).22 The amine 7 was obtained by reduction of
the corresponding glycosyl azide using propane dithiol32 in the pres-
ence of N,N-diisopropylethylamine (DIPEA), which promotes the
reduction and prevents anomerization of the glycosyl amine.33 The
glycopeptide hydrazide was deprotected after 16 h and purified by
HPLC, giving 8 in a yield of 30%. The yield for the coupling in solution
barely exceeded the overall yield obtained after the aspartylation of
EPO 1-28 on the solid phase (24% for the biantennary N-glycan
nonasaccharide vide supra). We suspected that impurities were
responsible for the moderate yield of glycopeptide 8. Because
glycosylamine 7 was prepared from the corresponding glycosyl azide
6, which was purified by HPLC,28 we focused on increasing the purity
of the selectively deprotected peptide 5.
However, the solubility of the selectively deprotected aspartyl
peptide 5 in MeOH was low, whereas the fully protected precursor
4 showed satisfactory solubility. In CH3CN, both peptides 4 and
5 were poorly soluble. Thus, preparative purification conditions for
4 were initially investigated on a C8 column using MeOH/water as
F IGURE 2 Synthesis of erythropoietin (EPO) 1-28 glycopeptide hydrazide 8. The 1-28 peptide was assembled by Fmoc-solid-phase synthesis
on a trityl-ChemMatrix resin, cleaved, and converted to the hydrazide 4. Selective cleavage of the phenylisopropyl ester rendered the aspartyl
peptide 5, which was coupled with the complex-type glycosyl amine 7. After global deprotection, the glycopeptide hydrazide 8 was obtained. On
the right side, the high-performance liquid chromatography (HPLC) traces from the HPLC–MS analysis of the peptides are shown
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an eluent. With the use of an isocratic elution (95% MeOH/water),
peptide 4 could be separated from a number of overlapping peaks
with shorter retention time.
Owing to the broad shape of most of the peaks and low repro-
ducibility, a nonaqueous26 mixture of organic solvents (70%
CH3CN/MeOH isocratic) was tested for the purification, which sepa-
rated 4 reliably and additionally provided 11 minor fractions
(Figure 3C).
Because the masses of the protected peptides in the minor frac-
tions could not be determined by LC–MS directly, the fractions were
separately deprotected and then analyzed. HPLC–MS revealed that all
the peaks eluting prior to peptide 4 corresponded to truncated pep-
tides. Only the two fractions with longer retention times gave a higher
mass than the target peptide 4d (Data S10b). The peptide 4 purified
by HPLC resulted in a significantly increased purity of 4d where only
traces of the previously observed side products were visible
(Figure 3E). Despite a good separation of the side products on a
10-mg scale using a 2 × 25-cm C8 column, the purification of amounts
over 15 mg decreased the resolution significantly. Thus, another sta-
tionary phase was tested. Gratifyingly, a polystyrene-based HPLC
column using a nonaqueous gradient system (0–40% CH3CN/MeOH)
also provided 4 in similar purity as before (Figure 3E). In a single run,
over 30 mg of 4 could be purified over a 2.5 × 30 cm Nucleogel col-
umn, removing many side products and contaminants mainly with
shorter retention times.
Subsequently, the phenylisopropyl ester of peptide 4 purified by
HPLC was selectively removed by 1% TFA/DCM, and the resulting
peptide 5 was aspartylated using glycosyl amine 7. To our delight, the
final yield of glycopeptide 8 was raised to 60%, thus virtually doubling
the yield in this step. It can be assumed that the numerous side prod-
ucts previously present in crude 5 (no HPLC) were also converted to
glycopeptides and other products, which needed to be removed in the
final HPLC step, thus lowering the coupling yield considerably.
We next attempted to also increase the purity of 5 by HPLC
because the selective deprotection of 4 under acidic conditions
might give rise to unwanted side products. The cleavage of the
Asp24 PhiPr group of 4 under different conditions was monitored
by HPLC–MS. The use of 1% TFA/DCM led to rapid deprotection
and also to the appearance of additional products after prolonged
incubation (more than 5 min). This deprotection was dependent on
F IGURE 3 High-performance liquid chromatography (HPLC) conditions for the purification of protected hydrazide 4: A, standard LC–MS
conditions (C8, CH3CN/H2O gradient); B, preparative HPLC (C8, MeOH/H2O isocratic); C, preparative HPLC (C8, CH3CN/MeOH isocratic); D,
preparative HPLC (polystyrene, CH3CN/MeOH gradient); E, UPLC–MS of peptide 4 (purified by HPLC) after deprotection; F, synthesis of
glycopeptide hydrazide 8 starting from 4 purified by HPLC; the yield is calculated based on the glycosylamine 7 (1 eq.), because peptide 5 was
used in excess (1.5 eq.) G, LC–MS of crude 8 after the pseudoproline-assisted Lansbury aspartylation starting from 4 purified by HPLC; the excess
of peptide 5 (1.5 eq.) increases the peak of deprotected peptide 4d in the chromatogram
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the concentration of peptide 4 with significantly less side products
in a 3 mM solution of 4 compared with 1 mM of 4. In contrast, we
found a clean and concentration-independent deprotection of 4 using
neat hexafluoroisopropanol (HFIP) over 6 h without significant
amounts of side products even after 48 h of incubation.34 The high
selectivity during the deprotection can be attributed to the low acid-
ity of HFIP (pKa 9.3),35 providing milder reaction conditions than 1%
TFA/DCM.
For the purification of 5 by nonaqueous HPLC, the poor solubil-
ity of 5 in neat MeOH was improved by dissolving 5 in a larger vol-
ume of MeOH containing DIPEA. However, the use of DIPEA in the
loading solution resulted in a strong tailing of the major peaks elut-
ing from the polystyrene-based Nucleogel column (0–21.5%
CH3CN/MeOH). Finally, a concentrated solution of 5 in DMF was
applied in the loading step resulting in symmetric and sharp peaks.
The gradient profile of the chromatography was adjusted accord-
ingly by adding a conditioning step with 0% acetonitrile over 20 min
after the loading. This procedure allowed the purification of 5 in
amounts of up to 50 mg per run. An analytical deprotection of
5 showed a further reduction of side products in LC–MS
(Figure 4D).
Peptide 5 purified by HPLC was subsequently tested in a
Lansbury aspartylation with the biantennary glycosylamine 7 (Figure 4).
After coupling, deprotection and purification the isolated yield was
further improved (71%), indicating that impurities contained in the
selectively deprotected peptide 5 that are removable by HPLC are the
cause of low yields in pseudoproline-assisted Lansbury aspartylations.
Because the N-glycans of EPO are mainly of the tetraantennary com-
plex type, a synthetic tetraantennary glycosylamine 1036 (1 eq.) was
coupled to purified 5 (1.3 eq.). The reaction was carried out for 16 h
F IGURE 4 High-performance liquid chromatography (HPLC) conditions for the purification of protected hydrazide 5 and aspartylation of the
purified peptide 5: A, peptide 5 obtained by deprotection of 4 in neat hexafluoroisopropanol (HFIP) monitored by LC–MS (C8, CH3CN/H2O
gradient); B, preparative HPLC of 5 (Nucleogel, CH3CN/MeOH gradient); C, analysis of 5 (purified by HPLC) by LC–MS: (C8, CH3CN/H2O
gradient); D, deprotection of 5 (purified by HPLC) gave 4d, LC–MS: (C8, CH3CN/H2O gradient); E, synthesis of biantennary glycopeptide
hydrazide 8 using peptide 5 purified by HPLC; F, synthesis of tetraantennary glycopeptide hydrazide 11 using peptide 5 purified by HPLC; G,
preparative HPLC of crude glyopeptide hydrazide 8 after deprotection; H, preparative HPLC of crude glyopeptide hydrazide 11 after
deprotection
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and was subsequently deprotected with a TFA cocktail. After workup
and purification, nearly 5 mg of the EPO 1-28 glycopeptide 11 con-
taining a galactosylated tetraantennary N-glycan was isolated,
corresponding to a yield of 65%.
3 | CONCLUSION
In summary, the yields of EPO 1-28 glycopeptide hydrazides by con-
vergent synthesis were found to depend strongly on the purity of the
selectively deprotected aspartyl peptide. Conditions were established
to monitor the synthesis and also purify the peptide hydrazides by
nonstandard conditions (nonaqueous reversed-phase chromatogra-
phy). With the protected peptides purified by HPLC, the
pseudoproline-assisted Lansbury aspartylations proceeded in high
yields and thus permitted the rapid and efficient derivatization of a
single peptide with the desired glycosyl amines. Because the solubility
of protected peptides is affected by the sequence and the protecting
groups, purification schemes need to be established for each peptide
individually.
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